- Home
- IMUX vs ARCL Comparison
IMUX vs ARCL Comparison
Compare IMUX & ARCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMUX | ARCL |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 178.4M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IMUX | ARCL |
|---|---|---|
| Price | $16.27 | $9.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 140.8K | 31.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $9.88 |
| 52 Week High | $16.86 | $9.96 |
Technical Indicators
Market Signals| Indicator | IMUX | ARCL |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 65.16 |
| Support Level | $0.74 | $9.88 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.04 | 0.01 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 90.27 | 100.00 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
About ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.